Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001209191-18-049373
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-09-04 19:39:21
Reporting Period:
2018-08-30
Accepted Time:
2018-09-04 19:39:21
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1619087 Steadymed Ltd. STDY Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1636975 W. David Nassif C/o Steadymed Therapeutics, Inc.
2603 Camino Ramon, Suite 350
San Ramon CA 94583
Evp And Cfo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Disposition 2018-08-30 22,157 $4.46 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Stock Option (Rt to Buy) Disposition 2018-08-30 3,100 $0.00 3,100 $3.61
Ordinary Shares Stock Option (Rt to Buy) Disposition 2018-08-30 159,642 $0.00 159,642 $3.61
Ordinary Shares Stock Option (Rt to Buy) Disposition 2018-08-30 51,832 $0.00 51,832 $5.84
Ordinary Shares Stock Option (Rt to Buy) Disposition 2018-08-30 40,000 $0.00 20,000 $2.74
Ordinary Shares Stock Option (Rt to Buy) Disposition 2018-08-30 15,987 $0.00 15,987 $3.65
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2019-07-19 No 4 J Direct
0 2020-05-01 No 4 J Direct
0 2022-01-25 No 4 J Direct
0 2026-06-17 No 4 J Direct
0 2027-12-28 No 4 J Direct
Footnotes
  1. Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding restricted share unit was converted into the right to receive (1) a cash payment equal to (x) $4.46, multiplied by (y) the total number of shares subject to such restricted share unit and (2) a number of CVRs equal to the total number of shares subject to such restricted share unit.
  2. Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding in-the-money option, whether vested or unvested, was converted into the right to receive (1) a cash payment equal to (x) the excess, if any, of $4.46 over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time and (2) a number of CVRs equal to the total number of shares subject to such option immediately prior to the Effective Time.
  3. Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding out-of-the-money option, whether vested or unvested, was converted into the right to receive a cash payment, if and when the Milestone is achieved, equal to (x) the excess, if any, of the sum of (1) $4.46 and (2) the contingent consideration actually payable per CVR over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time.